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Key Learning Points: 
▪ Obesity seems to increase the risk of developing severe dengue and as the two 
epidemics converge, it is important to understand why.  
▪ Obesity has been shown to reduce AMPK activity and cause cellular stress, which 
could allow for enhanced viral replication and additional pathology  
▪ In obese patients, the chronic elevation of pro-inflammatory adipokines leads to 
chronic inflammation and thus may contribute to dengue pathophysiology  
▪ Obesity causes additional stress and dysfunction to endothelium. This in 
combination with dengue induce dysfunction and degradation of the glycocalyx 
could lead to great vascular leakage.  
▪ Obesity alters immunomodulation, polarising the immune system to a more pro-
inflammatory response while also impairing adaptive and innate cellular responses, 
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Dengue virus (DENV) is a medically important flavivirus and the aetiological agent of Dengue, a 
normally self-resolving febrile illness that, in some individuals, can progress into Severe Dengue (SD), 
a life-threatening disorder that manifests as organ impairment, bleeding and shock. Many different 
risk factors have been associated with the development of SD, one of which is obesity. In many 
countries where DENV is endemic, obesity is becoming more prevalent, therefore SD is becoming an 
increased public health concern. However, there is a paucity of research on the mechanistic links 
between obesity and SD. This is a narrative review based on original research and reviews sourced 
from PubMed and Google Scholar. Four key areas could possibly explain how obesity can promote 
viral pathogenesis. Firstly, obesity downregulates AMP-Protein Kinase (AMPK), which leads to an 
accumulation of lipids in the endoplasmic reticulum (ER) that facilitates viral replication. Secondly, the 
long-term production of pro-inflammatory adipokines found in obese individuals can cause 
endothelial and platelet dysfunction and can facilitate SD. Thirdly, obesity could also cause endothelial 
dysfunction in addition to chronic inflammation, through the production of reactive oxygen species 
(ROS) and possible damage to the glycocalyx found in the endothelium. Finally, obesity has several 
effects on immunomodulation that reduces NK cell function, B and T cell response and increased pre-
disposition to stronger pro-inflammatory cytokine responses after viral infection. Together, these 
effects can lead to greater viral proliferation and greater tissue damage both of which could contribute 
to SD. The four mechanisms outlined in this review can be taken as reference starting points for 
investigating the link between obesity and SD, and to discover potential therapeutic strategies that 
can potentially reduce disease severity. 
Background 
Dengue virus (DENV) is one of the most important arboviruses that results in significant morbidity and 
mortality globally. An estimated 100 million clinically apparent (total 400 million) infections occur 
annually leading to an estimated 50,000 deaths per year (1). With geographical expansion of the Aedes 
mosquito vector, the burden of the disease is expected to increase with time.  DENV is a Flavivirus and 
has 4 distinct serotypes (DENV1-4) Dengue usually presents as a febrile illness, accompanied by 
headaches, nausea, vomiting, joint pain, muscle pain, and minor bleeding. A small proportion of cases 
however, progress into Severe Dengue (SD) which manifests as organ impairment, bleeding and 
plasma leakage leading to shock which can be life-threatening (2). Several different risk factors have 
been identified for the development of severe dengue, including age, gender, secondary infections, 
host and viral genetics, and presence of co-morbidities such as hypertension and diabetes (2). 
Recently, obesity has been proposed as a potential risk factor for SD. A systematic review and meta-
analysis of paediatric patients published in 2018 found that obesity produced an odds ratio for SD of 
1.38 (1.10-1.73, 95% Confidence interval)(3)(image 1). In addition, another recent study conducted in 
Kerala, India on the outcomes of pregnant dengue patients has also highlighted overweight patients 
having a significantly higher rate of adverse outcomes(4). The plausible association between obesity 
and SD is particularly concerning as while DENV mainly affect low- and middle-income countries 
(LMICs) (1), many of these countries are currently experiencing a large obesity epidemic(5). There has 
also been a marked increase in the rates of obesity in all areas of the globe between 1990-2010 with 
some of the largest increases being in Latin America, the Caribbean, East Asia, and the Pacific(6). The 
main drivers behind this recent increase in prevalence include (i) changes in nutritional availability 
with traditional diets being replaced with processed food high in fat, salt, and sugar, (ii) reduced prices 
that promote habits like frequent snacking and (iii) reduction in physical activity as jobs have shifted 
form manual labour to sedentary positions(6). This trend is further compounded by differences in 
obesity prevalence between rural and urban areas, with urban areas seeing higher rates of both 




Given the potential increased risk of developing SD associated with obesity, it seems likely that as the 
obesity epidemic continues, a greater burden will be placed on healthcare in dengue-endemic 
countries. Thus, it is vital to understand the pathophysiological mechanisms behind the association 
between the two. Dissecting the mechanisms involved will also allow for identification of novel 
therapeutic targets that can reduce the burden or severity of SD. Investigating the pathological 
mechanisms of dengue and the pathways leading to severe disease remains challenging, due to the 
lack of a suitable animal model which accurately recreates the transient increased capillary 
permeability syndrome that is seen in humans (2). . Despite this, several different pathophysiological 
mechanisms have been characterised and are increasingly understood. DENV pathogenesis primarily 
acts through DENV’s effect on the innate and adaptive immune system, through the disruption of the 
glycocalyx and by directly causing endothelial dysfunction. The glycocalyx layer is a semi-permeable 
membrane that can actively regulate the permeability of the endothelium and can regulate the 
diffusion of water and small solutes while also preventing large macromolecules for diffusing across 
the endothelium (8). Severe manifestations in dengue patients usually occur when the viremia begins 
to decline, during which time, peak endothelial leakage and viral control coincide with a cytokine 
storm (high circulating levels of pro-inflammatory cytokines and Tumour-necrosis factors (TNFs)) 
which likely contribute to endothelial dysfunction (9). Another explanation for plasma leakage is the 
binding of viral protein NS1 to the glycocalyx layer of the endothelium, where the glycocalyx layer is 
subsequently degraded by NS1 through the shedding of heparan sulphate proteoglycans(10), 
increasing endothelial permeability that ultimately leads to plasma leakage(10).  Recently, the 
bioavailability of nitric oxide (NO) during the early stages of infection have been found to correlate 
with SD outcome. Though the mechanisms behind the loss of NO bioavailability are not yet fully 
understood, the reduction of NO caused by DENV infection may also restrict vasomotor function, and 
glycocalyx loss resulting in plasma leakage (11). Finally, secondary infection (where an infected patient 
has been previously infected with a different DENV serotype) is associated with increased risk of SD. 
Cohort studies now support the role of antibody-dependent enhancement (ADE) in SD outcome 
(12),where sub-neutralizing concentrations of cross-reactive antibodies can opsonize DENV infection 
into Fc-receptor expressing myeloid cells, resulting in increased viral replication and inflammatory 
responses that exacerbates dengue disease. In addition, the secondary T-cell response in secondary 
infections is often dysfunctional due to the activation of cross-reactive T-cells generated during the 
primary DENV infection. This results in the generation of T cells with low avidity towards the DENV 
serotype responsible of the secondary infection which delays viral clearance and allows for an 
increased viral load(9).  
With our current knowledge of the molecular processes that can lead to dengue pathogenesis, there 
are a number of possible ways obesity could affect these processes that can increase their 
susceptibility to the development of SD. This review will focus on four possible mechanisms through 
which obesity acts as a risk factor in the development of SD. These mechanisms include altered AMPK 
expression and activity, the production of pro-inflammatory adipokines, increased oxidative stress 
that leads to endothelial dysfunction and the effects on immunomodulation.     
 
The potential role of AMPK dysregulation 
Adenosine Monophosphate (AMP)-Activated Protein Kinase (AMPK) is a major regulator of cellular 
energy homeostasis with a diverse range of functions including regulating lipid metabolism, protein 
synthesis, glucose metabolism, autophagy, redox regulation, and has been linked to anti-aging and 
anti-inflammatory properties (13).  AMPK activity and expression is controlled and influenced by a 
number of external factors including nutrition, caloric intake, exercise, aging, and 




In obesity, AMPK is often downregulated, contributing to insulin resistance, leptin (a satiety and anti-
obesity hormone released by adipocytes to prevent over-nutrition by primarily acting on the 
hypothalamus) resistance, and other metabolic disorders (13, 14). There are two possible mechanisms 
that cause AMPK to be downregulated in obesity. The first is the effect of overnutrition, where the 
accumulation of glucose, fatty acids and amino acids leads to the suppression of AMPK via a variety of 
mechanisms, including phosphorylation of specific amino acid residues, ubiquitination of specific 
amino acid residues and sub-cellular protein localisation (13). The second way is through the chronic 
inflammation that is often induced in obesity. The mechanism of action is thought to be the increased 
induction of pro-inflammatory cytokines such as TNF-α and IL-6 which in turn increase the activity of 
SOSC3 and PP2C, leading to both decreased AMPK phosphorylation and AMPK protein expression (13, 
15)  
The role of AMPK in DENV infection is still being investigated.  Several studies have shown that DENV 
downregulates AMPK activity in order to prevent lipid metabolism and increase lipid quantities 
available to form the lipid envelope during viral replication. This view is supported by a series of papers 
where the induction of AMPK activity through pharmacological means, severely impacted viral activity 
and replication (16, 17). The main mechanism used by DENV to downregulate AMPK is through the 
prevention of AMPK Thr-172 phosphorylation, inhibiting the phosphorylation of HMGCR which 
increases its activity. The increase in HMGCR activity subsequently resulted in the accumulation of 
cholesterol within the ER, allowing for enhanced viral replication (16). This evidence is further 
supported by papers detailing molecules that increase the activity of AMPK, by phosphorylating the 
Thr-172 residue they have antiviral properties against DENV (17). However, there is also some recent 
evidence suggesting that the inhibition of AMPK activity could also lead to a reduction in viral 
replication. Interestingly, DENV can also induce AMPK signalling while supressing mTOR signalling in 
order to induce lipophagy which is required for viral replication (18, 19). This process involves the 
recruitment of autophagosomes to lipid-droplet bound protein AUP1. The process of lipophagy then 
occurs, releasing fatty acids which are then processed in the mitochondria via β-oxidation to release 
ATP(19).  
While the exact role of AMPK in DENV infection is not fully understood, obesity could play a role in 
enhancing DENV infection. Obese individuals already have a low AMPK activity, which is further 
downregulated by DENV in order boost ER cholesterol levels (16), thus  facilitating  viral replication 
that could lead to more severe disease. However, this mechanism relies on the downregulation of 
AMPK not being detrimental to viral replication by inhibiting lipophagy and thus reducing the rate of 
replication (fig 1). Another possibility is that the suppressed AMPK expression and function may result 
in reduced capacity to cope with cellular stress caused by DENV infection, inducing maladaptive ER 
stress and inflammatory responses that may promote SD outcome (20, 21).  
Role of pro-inflammatory adipokines 
One of the major roles of adipocytes is to link metabolism with immunity and vice versa. This is 
achieved through the release of adipokines, a complex network of soluble factors (22). Many of these 
adipokines have pro-inflammatory properties, with two of the most important being Leptin and 
Resistin (22).  
Leptin is an adipokine with distinct central (acting in the hypothalamus) and peripheral (acting outside 
the hypothalamus) roles. Its role within the immune system is the increased secretion of pro-
inflammatory cytokines including TNF-α, IL-6 and IL-12(23). The expression of leptin mRNA in adipose 
tissue can be further upregulated by pro-inflammatory cytokines such as TNF-α and IL-1β(23). In obese 
individuals, serum levels of leptin can remain chronically elevated which in turn can then contribute 
to chronic inflammation(23). 
Similarly, resistin is a pro-inflammatory cytokine which induces the secretion of TNF-α, IL-6 and IL-




being higher in peripheral-blood mononuclear cells (PBMCs) than in adipocytes(22).  Endothelial cells 
have also been shown to be resistin sensitive, upregulating the expression of VCAM1 and ICAM1 
allowing for additional transendothelial migration(22). In obese patients, both of these adipokines are 
found to be at elevated levels and this gives rise to low-grade chronic inflammation(22). This low-
grade ongoing form of inflammation been linked to many different disorders, including metabolic 
disorder, insulin-resistance disorders, various cancers, immunity disorders and endothelial 
dysfunction(22).   
The increased levels of inflammation caused by both leptin and resistin could modify DENV infection 
through two possible mechanisms. First, increased inflammation causes higher levels of C-Reactive 
Protein (CRP) to be present in serum(25). CRP is a major marker for inflammation, with CRP levels 
increasing 1000-fold during certain bacterial infections. CRP has also been associated with more 
severe clinical outcomes in dengue infections (Vuong et al BMC medicine in press). As well as being a 
marker of inflammation, CRP can also play a role in the pathogenesis, as it processes key functions 
that may leave a patient more vulnerable to severe dengue. The increased CRP levels caused by DENV 
infection can lead to the downregulation of endothelial Nitric Oxide Synthase (eNOS) expression, 
attenuating NO production, loss of vasomotor function (25), and early endothelial dysfunction that is 
associated with severe plasma leakage in dengue (11). With the elevated levels of CRP associated with 
obesity, the effects of CRP on eNOS and NO production is likely to be further amplified, thus 
exacerbating disease severity. 
Secondly, the elevated levels of leptin and resistin encourage the production of pro-inflammatory 
cytokines, while other adipokines can lead to an increased production of anti-inflammatory cytokines, 
particularly IL-10(22). Thus, obesity could lead to an imbalance of pro- and anti-inflammatory 
cytokines with both groups of cytokines being produced in excess(22). In dengue patients, this 
imbalance has been associated with the development of haemorrhagic manifestations. That elevated 
levels of these cytokines are found in obese patients could thus prime these individuals to more severe 
manifestations  (26).   
Endothelial dysfunction  
One of the key factors in determining DENV pathology is the process of endothelial dysfunction and 
increased capillary permeability, causing plasma leakage and coagulopathy (11). One of the ways 
DENV can cause endothelial dysfunction is through oxidative stress and the associated tissue damage. 
During the febrile stage of infection, key markers of oxidative stress include Hydroxyeicosatetraenoic 
acids (HETEs) in plasma and F2-isoprotanes (F2-IsoPs) in urine(27). Other studies have also indicated 
elevated lipid peroxidation products such as protein carbonyls and malondialdehydes to be associated 
with SD (28). While it is not certain whether the effects of these reactive oxygen species (ROS) released 
during DENV infection are advantageous or deleterious for DENV pathogenesis. Oxidative stress has 
however been shown to cause damage to endothelial cells and has been previously linked with 
cardiovascular events such as atherosclerosis(29). Another proposed mechanism of DENV induced 
capillary leak involves disruption to the glycocalyx layer. During DENV infection, both whole virus and 
DENV NS1 protein have been shown to bind to heparan sulphate, a key structural element of 
glycocalyx(10). This disruption to the glycocalyx layer results in leakage of plasma and key serum 
proteins including albumin, with smaller proteins seeing more severe leakage than large proteins(30). 
In patients who develop shock as a result of SD, high levels of heparan sulphate can be found in the 
patient’s urine, and high levels of syndecan1 (31) (Yacoub S PhD thesis ), further suggesting the extent 
of damage to the glycocalyx is a major contributor to the development of SD (10). The third way DENV 
can cause endothelial dysfunction is through the disruption of endothelial-dependent vasodilation. In 
particular, levels of NO availability are reduced during the febrile stages of DENV infection, along with 
the NO-precursor l-arginine(11). Another way of endothelial dysfunction could involve  the CRP 




In obese individuals, chronic inflammation caused by adipokines can result in the downregulation of 
eNOS, thereby reducing the production of NO and diminishing the capacity for vasomotor function 
(22). Additionally, the decoupling of eNOS has also been shown to increase production of reactive 
oxygen species (ROS) including H2O2, OH- and ONOO- , all of which can cause oxidative damage, 
resulting in further endothelial dysfunction(32). While damage to the glycocalyx layer has not been 
directly investigated in obese individuals, the disrupted glycocalyx layer integrity is often seen in 
patients with diabetes and metabolic syndrome. While the precise mechanisms still remains unclear, 
it  is thought that an increase in Transforming Growth Factor-β (TGF-β) can alter the synthesis of matrix 
proteins and thus affecting glycocalyx integrity (33). Interestingly,  TGF-β has been observed to 
correlate with the body-mass index (BMI), which provides support that obesity may also impact 
glycocalyx integrity by altering TGF-β expression (34).   
Immunomodulation  
With the defined biological links between adipocytes and the immune system, it is perhaps not 
surprising that obesity has been found to alter the immune system, and specifically 
immunomodulation in several different ways. These changes can include altered antibody repertoires, 
changes to NK cell activation, altered CD8+ T memory cell formation, and altered T cell metabolism(35-
37).  
It has been found that obesity has a similar level of antibody response attenuation as aging does, with 
a few key markers defining the difference (35). Firstly, obese individuals have a decreased subset of 
anti-inflammatory B-cells, while also having increased levels of pro-inflammatory B-cells. Total B-cell 
function is also impaired with reduced AID activity. The reason for this seems to be because of 
increased production of pro-inflammatory cytokines, particularly intracellular TNF-α, which all 
negatively associate with AID activity in stimulated B-cells due to the upstream inhibition of AMPK 
(35). This fact may impact DENV infection in two important ways. The production of more pro-
inflammatory antibodies seems likely to cause tissue damage and endothelial dysfunction as 
previously discussed. And, perhaps a more interesting way, is that this process may affect antibody-
dependent enhancement and as a result cause more severe disease(12). It is possible that the reduced 
activity of B-cells found in obese individuals, could result in a reduced protective antibody-titre and 
thus augment the risk of antibody-dependent enhancement and a greater risk of SD development. 
Obesity also leads to an increase in inflammatory monocytes, as evidenced by increased CD16+ 
circulating monocytes in humans (38, 39), and increased accumulation of M1 activated macrophages 
in adipose tissues (40). Monocytes and macrophages are known to be the primary target cells for 
DENV. However, inflammatory monocyte and macrophage subsets have been shown to be more 
susceptible to DENV infection and induce greater proinflammatory responses such as IL-1β, TNF-a, IL-
6, IL-18, CCL2, 3 and 4 that may potentially exacerbate disease severity (41, 42). Thus, the systemic 
low-grade chronic inflammatory state in obesity may promote progression to SD by amplifying 
proinflammatory responses to DENV. 
Obesity has also been shown to severely impact T-cell repertoire, function and metabolism(36). Obese 
patients have been observed to have a reduced number of γδ T cells, with those present also exhibiting 
reduced functionality with impaired IL-2 receptor expression and INF-γ production(36). In addition, 
the function of regulatory T cells (Tregs) is also significantly inhibited and elevated leptin levels 
produce more pro-inflammatory T cell subtypes including: Th1, Th17 and cytotoxic T lymphocytes 
(CTLs)(36). These processes could exacerbate an already heightened T cell response observed during 
severe dengue leading to T cell apoptosis of dengue-specific T cells and inability to eliminate virus-
infected cells(43).  
Obesity alters T cell metabolism and T cell differentiation. Metabolism is a key driver of T cell 
differentiation, function and cytokine production and metabolic pathways influence the development 




of antigen-specific T cell populations and the generation of stable memory T cells is also supported by 
changes in metabolism (45). Thus, the metabolic dysregulation that occurs in the obese is likely to 
affect the anti-viral functions of the T cell response during dengue infection as well as the long-term 
survival of memory T cells. Obese children and adults display altered T cell and antibody responses to 
influenza vaccination (46). Similarly, obese mice display an impaired T cell response towards 
secondary influenza infection virus compared to their lean counterparts, with increased risks of 
infection  (47). Studies also show evidence of  impaired immune responses to vaccines such as 
hepatitis B, hepatitis A, rabies and tetanus in obese individuals (48). This leads to the attenuated 
proliferation of T cells during infection and thus an attenuated immune response(36). This could mean 
that a more prolonged and pro-inflammatory response is produced in obese patients during DENV 
leading to exacerbated activation of T cells with poor effector function while lacking key anti-viral T 
cell subtypes including γδ T cells, meaning that more damage is done to the sites of infection over 
longer periods of time, as it takes longer to clear the virus and contract the immune response. 
Finally, obesity is also known to impact the function of NK cells, key components of any anti-viral 
response during the early stages of infection. While short-term exposure to leptin has been shown to 
improve conjugation between NK cells and tumour cells as well as higher expression of TNF-related 
apoptosis inducing ligand(37); chronic exposure to leptin (which occurs in obese individuals) has been 
shown to impair NK cell immune functions as well as NK cell proliferation(37). NK cells from obese 
children were shown to be metabolically stressed and impaired in their cytotoxic capabilities 
compared to those from their non-obese counterparts (49). A recent study shows that NK cells from 
obese individuals are impaired in their cytotoxic abilities due to the uptake of lipids from the 
environment which induces a metabolic paralysis of the cells (50). As a result, in obese individuals the 
function of NK cells is heavily attenuated and thus the immune system’s ability to prevent the 
proliferation of DENV during early infection would be severely impaired. Furthermore, in Hepatitis B 
infection NK cell impairment was shown to associate with an exacerbated CD8+ T cell response, 
suggesting that NK cells play an immunomodulatory role on CD8+ T cells either through the 
elimination of virus-infected cells or through direct killing of anti-viral CD8+ T (51). Studies in mice also 
propose NK cells as rheostats modulating the anti-viral T cell response (52). 
Collectively, these different effects that obesity has on immunomodulation ultimately mean that 
DENV could proliferate with less resistance, may benefit from ADE, and that the immune system could 
ultimately cause far more tissue damage when compared to a non-obese patient.  
Conclusions 
As the incidence of obese individuals continues to grow in DENV endemic areas, it will become 
increasingly important to understand the mechanistic relationship behind the elevated risk of 
developing SD found in obese patients. It is important to piece together the information on the 
pathology of DENV and pair it with the information on how obesity can affect immunity, metabolism 
and endothelial function; in order to identify plausible mechanisms for further investigation. In this 
paper, a series of possible mechanisms have been identified focusing on a few key aspects, including 
altered cellular metabolism, endothelial dysfunction, chronic inflammation and immune modulation 
(table 1). 
Given the highly integrated nature of the immune system and adipose tissue, it seems likely that a 
combination of these different factors is responsible for the increased risk associated with being 
obese. However, it remains important to investigate each of these possible links to establish a 
correlation, and where possible, mechanistic models (fig 2) (table 1). A systems biology approach that 
employs and integrates various biological parameters such as transcriptomics, proteomics, 
metabolomics, flux analyses and epigenetics could thus be useful in deciphering the precise 
mechanisms involved in SD pathogenesis. The possible mechanisms detailed in this paper would thus 






This review is a non-systematic narrative review. PubMed (PM) was used as the primary search tool 
for both original research and review articles published between 2000-2019, with Google Scholar 
being used for supplementary information. The key search terms used and the number of hits for each 
database were: “Dengue”(PM=18,899), “Obesity and Dengue”(PM=25), “Obesity and Severe 
Dengue”(PM=14), “Obesity and LMICs” (PM=86), “Dengue Pathology”(PM=1919), “Obesity and 
AMPK”(PM=2,514), “Dengue and AMPK”(PM=6), “Obesity and Inflammation”(PM=23,645), “Obesity 
and Adipokines”(PM=18,057), “Inflammation and Dengue” (PM=595), “Inflammation and Endothelial 
Dysfunction”(PM=13,876), “Dengue and Endothelial Dysfunction”(PM=96), “Obesity and Endothelial 
Dysfunction”(PM=3,694), “Obesity and Immunomodulation”(PM=4,228), “Obesity and the Immune 
System”(PM=7,702), “Immune Response to Dengue”(PM=1,808). From these searches, the returns 
where organised by each database based on the relevance to the search term and the first 50 (where 
possible) were selected for review. The abstract and title for each of these papers was then checked 
for relevance to the topic being reviewed. Those that were found to be relevant were included in the 





    Tables and Figures  
  
Image 1: An obese paediatric patient suffering from severe 
dengue.  
Figure 1: Schematic showing how obesity can 
downregulate AMPK levels and AMPK phosphorylation, 
and mechanisms of how reduced AMPK levels may 





Table 1: Summary of review findings and relevant supporting literature  
Pathway Conditions of interest Alterations to biomarkers of interest Supporting papers 
Obesity AMPK↓ Jeon, 2016., Xu et al, 2012., Steinberg et al, 2006
DENV infection AMPK↓(Effect of DENV on AMPK activity remains controversial) Jimenez de Oya et al, 2018 (DENV decreases AMPK activity)., Soto-Acosta et al, 
2017(DENV decreases AMPK activity)., Jordan & Randell, 2017(DENV increases 
AMPK activity)., Randell, 2018(DENV increases AMPK activity)
Reduced AMPK activity ER Stress↑, Mitchondrial stress↑ Chan et al, 2019., Herzig & Shaw, 2018
Inflammation Obesity/Chronic 
Inflammation
Leptin↑, resistin↑, TNF-α↑,IL-6↑, CRP↑, IL-1β↑, IL-12↑, VCAM-1↑, ICAM-1↑, IL-10↑,  eNOS↓, 
NO↓
Tilg & Moschen, 2006., Iikuni et al, 2008., Bokarewa et al, 2005., Sproston & 
Ashworth, 2018
DENV infection HETEs↑, F2-IsoPs↑, ROS↑, endothelial dysfunction↑, NS1↑, Heperan Sulphate Proteoglycans↑, 
EGL dysfunction↑, Albinum leakage↑, transferrin leakage↑, urinary heperan sulphate↑
Seet et al, 2009., Heitzer et al, 2001., Puetra-Guardo et al, 2016., Wills et al, 
2004
Severe Dengue NO↓, arginase-1↑, L-arginine↓, RHI↓, plasma leakage↑, loss of coordination:IL-6~ IL-8~ IL-10 Yacoub et al, 2017., Iani et al, 2016
Obesity  eNOS↓, Glycocalyx intergrity↓, TGF-β↑, BMI↑  Avogaro & de Kreutzenburg, 2005., Bakker et al, 2009., Torun et al, 2007
B-cell Response: AID↓, TNF-α↑, AMPK↓, B-cell response↓,  IgG reponse↑, 12 month-post 
vaccination Antibody titre↓
Frasca et al, 2017.,  Sheridan et al, 2012.,
Macrophage Response: Circulating CD16+ Monocytes↑, M1 Macrophages↑, M2 Macrophages↓ Jordan et al, 2019., Poitou et al, 2011., Lumeng et al, 2007.,
T-cell Resposne: γδT-cells↓, IL-2R↓, IFN-γ↓, Th1 cells↑, Th17 cells↑, CTLs↑,  CD8+ T-cell 
activation↓, T-cell response to Influenza Vaccine↓,Vaccine Response↓
Green & Beck, 2017., Pearce & Pearce, 2013., Pearce et al, 2009., Sheridan et 
al, 2012., Rebeles et al, 2019., Tagliabue et al, 2016.,
NK cell Response: NK cell immune functions↓, Peripheral NK cell frequency↑, NK cell activation↑, 
NK metabolic stress↑, NK cell metabolic paralysis↑, envirnomental lipid uptake↑, CD8+ T-cell death 
ligand↑, NK mediated CD8+ T-cell deletion↑, NK cells act as Rheostats for CD8+ T-cell  
Wrann et al, 2012., Tobin et al, 2017., Michelet et al, 2018., Peppa et al, 2013., 
Waggoner et al, 2011
DENV infection Antibody titre (within a specific range), ADE↑, M1 Macrophage Produced Cytokines↑, GM-
Macrophage Susceptibility↑ 




Figure 2: Summary of the potential pathophysiological 
mechanisms driving the increased risk f severe dengue 




List of Abbreviations: 
DENV: Dengue Virus 
SD: Severe Dengue 
LMICs: Low- Middle-Income Countries  
TNF: Tumour Necrosis Factor  
NO: Nictric Oxide  
ADE: Antibody Dependent Enhancement  
AMP: Adenosine Monophosphate 
AMPK: AMP-Activated Protein Kinase 
IL: Interleukin  
PBMCs: Peripheral-Blood Mononuclear Cells  
CRP: C-Reactive Protein  
eNOS: endothelial Nitric Oxide Synthase   
HETEs: Hydroxyeicosatetraenoic acids 
F2-IsoPs: F2-isoprotanes 
ROS: Reactive Oxygen Species  
TGF: Transforming Growth Factor  
BMI: Body-Mass Index  
NK: Natural Killer  
Tregs: Regulatory T-cells 
CTLs: Cytotoxic T-Lymphocytes   
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